Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Benzodiazepine or Phenethylamine or [[:Category:IBS_treatments|IBS-C treatment]]

Use the filters below to narrow your results.

generic:
brand:
None (34) · Dalmane (1) · Doral (1) · Halcion (1) · Lexotan (1) · Librium (1) · Linzess (1) · Mogadon (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Very potent 5-HT2A agonist; long duration (1) · '"`UNIQ--vote-00001197-QINU`"' Extracellular cGMP separately activates submucosal sensory afferents in a way that reduces visceral pain perception, distinguishing linaclotide from purely osmotic laxatives in IBS-C. Diarrhea is the dose-limiting effect'"`UNIQ--ref-00001198-QINU`"'. (1)
uses:
None (48) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) · '"`UNIQ--vote-00001199-QINU`"', '"`UNIQ--vote-0000119A-QINU`"', '"`UNIQ--vote-0000119B-QINU`"' (1)
starting dose:
None (48) · 0.25 mg (1) · 145 mcg PO once daily for chronic idiopathic constipation; 290 mcg daily for IBS-C; pediatric 72 mcg daily (1)
preparations:
None (48) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 72, 145, 290 mcg capsules (1)
fda max:
None (48) · 10 mg/d (1) · 290 mcg/d (1)
routes:
None (47) · insufflated (1) · Oral (3) · PR (1)
onset:
None (47) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · 45-75 min (oral) (1) · Bowel movement within 1 week; abdominal pain improvement over weeks (1)
duration:
None (47) · 24 hours (1) · 4-8 h (1) · 6 h (immediate-release); ~11 h (extended-release) (1)
halflife:
None (47) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · Not meaningfully described (negligible systemic absorption — the drug acts locally and is degraded in the GI tract)'"`UNIQ--ref-0000119C-QINU`"' (1) · Not well characterized (1)
bioavailability:
None (47) · 80-90% oral (1) · Negligible systemic absorption'"`UNIQ--ref-0000119D-QINU`"' (1) · Not well characterized (1)
pregnancy:
None (47) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Limited data; minimal systemic absorption likely renders fetal risk low.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)
legal:
None (47) · Schedule IV (US) (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' contraindicating use in children <2 years (lethal dehydration in animal studies)'"`UNIQ--ref-0000119E-QINU`"' (1)

Showing below up to 50 results in range #1 to #50.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"